Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.

Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Thursday 19 November →